Expand all sections

Cobolimab

Extended indication Cobolimab in combination with dostarlimab and docetaxel for second line, third line treatment of adv
Therapeutic value No estimate possible yet
Registration phase Clinical trials

Product

Active substance Cobolimab
Domain Oncology
Reason of inclusion New medicine (specialité)
Main indication Lung cancer
Extended indication Cobolimab in combination with dostarlimab and docetaxel for second line, third line treatment of advanced or metastatic EGFR-negative, ALK-negative, or ROS-1-negative Non-small cell lung cancer in adults and elderly who have progressed on prior anti-PD-(L)1 therapy and chemotherapy
Manufacturer GSK
Budgetting framework Intermural (MSZ)
Additional remarks Cobolimab is a monoclonal antibody against the inhibitory T-cell receptor, T-cell immunoglobulin and mucin domain-3 (TIM-3), with potential immune checkpoint inhibitory and antineoplastic activities.

Registration

Registration route Centralised (EMA)
ATMP No
Submission date 2025
Expected Registration 2026
Orphan drug No
Registration phase Clinical trials
Additional remarks Fabrikant verwacht indiening in 2025 en registratie in 2026.

Therapeutic value

Therapeutic value No estimate possible yet
Substantiation De resultaten moeten nog worden afgewacht. De verwachting is dat het mogelijk wel wat kan gaan betekenen omdat docetaxel niet erg effectief is.
References NCT04655976 (COSTAR Lung)

Expected patient volume per year

Patient volume

< 3,700

Market share is generally not included unless otherwise stated.
References NKR2021
Additional remarks In 2021 waren er 10.096 diagnoses NSCLC in Nederland. Dit betrof 1.727 patiënten in stadium I, 822 patiënten in stadium II, 2.231 patiënten in stadium III, 5.247 patiënten in stadium IV. Ongeveer 50% van de stadium III en stadium IV patiënten gaat door voor een tweede lijn therapie. Het zal ongeveer gaan om 3.700 patiënten.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.